The 'pill scare II' two years later

European Journal of Contraception and Reproductive Health Care

Volumn 2, Issue 3, 1997, Pages 149-159

  Balasch, J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Gestagens; Leiden mutation; Oral contraceptives; Third generation gestogens; Venous thromboembolism

Indexed keywords

ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

ATTITUDE TO HEALTH; CHEMICALLY INDUCED DISORDER; EPIDEMIOLOGY; EUROPE; HUMAN; MASS MEDIUM; REVIEW; RISK; RISK FACTOR; THROMBOEMBOLISM;

ATTITUDE TO HEALTH; BIAS (EPIDEMIOLOGY); CONTRACEPTIVES, ORAL, COMBINED; ESTROGENS; EUROPE; HEALTHY WORKER EFFECT; HUMANS; MASS MEDIA; PROGESTINS; RISK; RISK FACTORS; THROMBOEMBOLISM;

EID: 0031218092     PISSN: 13625187     EISSN: None     Source Type: Journal    
DOI: 10.3109/13625189709167470     Document Type: Article

References (76)

1. Grimes D. The safety of oral contraceptives: epidemiologic insights from the first 30 years. Am J Obstet Gynecol 1992; 166: 1950-4
2. Royal College of General Practitioners. Oral contraception and thromboembolic disease. J R Coll Gen Pract 1967; 13: 267-79
3. Inman WHW, Vessey MP, Westerhom B. Thromboembolic disease and the steroid content of oral contraceptives. A report to the Committee on Safety of Drugs. Br Med J 1970; 2: 203-9
4. Mishell DR. Oral contraception: past, present and future perspectives. Int J Fertil 1992; 37(Suppl.1): 7-18
5. Rebar RW, Zeseron K. Characteristics of the new progestogens in combination oral contraceptives. Contraception 1991; 44: 1-10
6. Balasch J. Los 'nuevos' y los 'viejos' progestágenos. Clin Invest Gin Obst 1992; 19: 127-38
7. ACOG. Technical bulletin. Hormonal contraception. Int J Gynecol Obstet 1995; 48: 115-26
8. Vessey MP. Benefits and risks of combined oral contraceptives. Methods Inf Med 1993; 32: 222-4
9. Serfaty D. Medical aspects of oral contraceptive discontinuation. Adv Contracept 1992; 8(Supp.1): 21-3
10. Committee of Safety of Medicines communication to doctors and pharmacists: Combined oral contraceptives and thromboembolism. 18 October 1995
11. Carnall D. Controversy rages over new contraceptive data. Br Med J 1995; 311: 1117-8
12. Guillebaud J. Advising women on which pill to take. Br Med J 1995; 311: 1111-2
13. MacRae K, Kay C. Third generation oral contraceptive pills. Br Med J 1995; 311: 1112
14. Spitzer WO. Data from transnational study of oral contraceptives have been misused. Br Med J 1995; 311: 1162
15. Craft N. Clots of trouble. Br Med J 1995; 311: 1172-3
16. Carnall D, Karcher H, Gunnar L, et al. Third generation oral contraceptives - the controversy. Br Med J 1995; 311: 1589-90
17. WHO collaborative study. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1575-82
18. WHO collaborative study. Effect of different progestogens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-8
19. Jick H, Jick SS, Gusewich V, et al. Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with different progestogen components. Lancet 1995; 346: 1589-93
20. Spitzer WO, Lewis MA, Heinemann LAJ, et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Br Med J 1996; 312: 83-8
21. Lewis MA, Spitzer WO, Heinemann LAJ, et al. Third generation oral contraceptives and risk of myocardial infarction: an international case-control study Br Med J 1996; 312: 88-90
22. Lidegaard O. Oral contraceptives and venous thromboembolism: an epidemiological review. Eur J Contracept Reprod Health Care 1996; 1: 13-20
23. Rekers H, Norpoth T, Michaels MA. Oral contraceptive use and venous thromboembolism: a consideration of the impact of bias and confounding factors on epidemiological studies. Eur J Contracept Reprod Health Care 1996; 1: 21-30
24. Crook D. Do different brands of oral contraceptives differ in their effects on cardiovascular disease? Br J Obstet Gynaecol 1997; 104: 516-20
25. McPherson K. Third generation oral contraception and venous thromboembolism. Br Med J 1996; 312: 68-9
26. Westhoff CL. Oral contraceptives and venous thromboembolism: Should epidemiologic associations drive clinical decision making? Contraception 1996; 54: 1-3
27. Lidegaard O, Milsom I. Oral contraceptives and thrombotic disease: impact of new epidemiological studies. Contraception 1996; 53: 135-9
28. Rosenberg L, Bégaud B, Bergman U, et al. Are third generation oral contraceptives safe? Hum Reprod 1996; 11:687-8
29. Spitzer WO. The future of oral contraceptives: research priorities. Hum Reprod 1996; 11: 688-9
30. Cohen J. Epidemiological disasters. Hum Reprod 1996; 11: 689-90
31. Kaper RF. Differences in venous thromboembolism - risks are related to causes other than product characteristics. Hum Reprod 1996; 11: 690-1
32. Michaels MA, Norpoth T. Health policy and third generation oral contraceptives. Hum Reprod 1996; 11: 691-2
33. Leader A. The public warnings on cardiovascular disease and third generation oral contraceptives were not justified. Hum Reprod 1996; 11: 692-3
34. Poindexter AN. Third-generation oral contraceptives and thromboembolism risk. Obstet Gynecol 1997; 89: 1028-30
35. Herings RMC, de Boer A, Urquhart J, et al. Non-causal explanations for the increased risk of venous thromboembolism among users of third generation oral contraceptives. Pharmacoepidemiol Drug Saf 1996; 5: S88
36. Lewis MA, Heinemann LAJ, MacRae KD, et al. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. Contraception 1996; 54: 5-13
37. Farmer RDT, Lawrenson RA, Thompson CR, et al. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997; 349: 83-8
38. Lidegaard O, Edström B. Oral contraceptives and venous thromboembolism: a case-control study. Eur J Contracept Reprod Health Care 1996; 1: 73
39. Vandenbroucke JP, Rosendaal FR. End of the line for "third-generation-pill" controversy? Lancet 1997; 349: 1113-14
40. Lidegaard O, Milsom I. Oral contraceptives and venous thromboembolism. Lancet 1997; 349: 1621
41. Lewis MA, Heinemann LAJ. Oral contraceptives and venous thromboembolism. Lancet 1997; 349: 1621-2
42. Szarewski A, Hollingworth B, Mansour D, Hampton N, Walling M. Oral contraceptives and venous thromboembolism. Lancet 1997; 349: 1622
43. Rossing J, Tans G, Nicolaes GAF, Thomassen M, van Oerle R, van der Ploeg P, et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997; 97: 233-8
44. Baulieu EE, Evers J, Fraser I, et al. Safety of modern oral contraceptives. Lancet 1996; 347: 258
45. van Lunsen HW. Recent oral contraceptive use patterns in four European countries: evidence for selective prescribing of oral contraceptives containing third-generation progestogens. Eur J Contracept Health Care 1996; 1: 39-45
46. Heinemann LAJ, Lewis MA. Increased risk estimates for venous thromboembolism under OCs with third-generation progestagens due to preferential prescribing? Pharmacoepidemiol Drug Saf 1996; 5: S59
47. Farmer RDT, Lawrenson RA, Hambleton IR. Oral contraceptive switching patterns in the United Kingdom: an important potential confounding variable in studies of venous thromboembolism. Eur J Contracept Reprod Health Care 1996; 1: 31-7
48. Arrighi HM, Hertz-Picciotto I. The evolving concept of the healthy worker survivor effect. Epidemiology 1994; 5: 189-96
49. Spitzer WO. The European Agency for the Evaluation of Medicinal Products. CPMP Bulletin 1995; 647
50. Thomas SHL. Mortality from venous thromboembolism and mycardial infarction in young adults in England and Wales. Lancet 1996; 348: 402
51. Vanderbroucke JP, Bloemenkamp KW, Helmerhorst FM, et al. Mortality from venous thromboembolism and myocardial infarction in young women in the Netherlands. Lancet 1996; 348: 401-2
52. Fanner RDT, Lewis M, Lunsen HW, et al. Oral contraceptives and mortality from venous thromboembolism. Lancet 1996; 348: 1095-6
53. Petiti DB, Sidney S, Bernstein A, et al. Stroke in users of low-dose oral contraceptives. N Engl J Med 1996; 335: 8-15
54. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multi-centre, case-control study. Lancet 1996; 348: 505-10
55. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Ischaemic stroke and combined oral contraceptives: results of an international, multi-centre, case-control study. Lancet 1996; 348: 498-505
56. Thorneycroft IH. Oral contraceptives and myocardial infarction. Am J Obstet Gynecol 1990; 163: 1393-7
57. The Writing Committee for the Second European Conference on Sex Steroids and Metabolism. Consensus development meeting 1995: combined oral contraceptives and cardiovascular disease.The Consensus Statement issued after the Second European Conference on Sex Steroids and Metabolism, Amsterdam, November 1995. Gynecol Endocrinol 1996; 10: 1-5
58. Speroff L, DeCherney A. The Advisory Board for the New Progestins. Evaluation of a new generation of oral contraceptives. Obstet Gynecol 1993; 81: 1034-47
59. Newton JR. Classification and comparison of oral contraceptives containing new generation progestogens. Hum Reprod Update 1995; 1: 231-63
60. Kluft C, Lansink M. Effect of oral contraceptives on haemostasis variables. Thromb Haemost 1997; 78: 315-26
61. Koster T, Rosendaal FR, Reitsma PH, Van derVelden PA, Briet E, Vanderbroucke JP. FactorVII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms. Leiden Thrombophilia Study. Thromb Haemost 1994; 71: 719-22
62. Pabinger I, Schneider B, and the GTH Study Group on Natural Inhibitors. Thrombotic risk of women with hereditary antithrombin-, protein C-, and protein S-deficiency taking oral contraceptive medication. Thromb Haemost 1994; 71: 548-52
63. Vandenbroucke JP, Koster T, Briët E, et al. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7
64. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, et al. Enhancement by factorV Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346: 1593-6
65. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-4
66. Balasch J, Reverter JC, Fábregues F, Tàssies D, Rafel M, Creus M, Vanrell JA. First-trimester repeated abortion is not associated with activated protein C resistance. Hum Reprod 1997; 12: 1094-7
67. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22
68. Hellgren M, Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995; 173: 210-13
69. Jespersen J. Plasma resistance to activated protein C: an important link between venous thromboembolism and combined oral contraceptives: a short review. Eur J Contracept Reprod Health Care 1996; 1:3-11
70. Rosendaal FR. Oral contraceptives and screening for factorV Leiden. Thromb Haemost 1996; 75: 524-5
71. Duchemin J, Pittet J, Tartary M, Beguin S, Gaussem P, Athen-Gelas M, et al. A new method based on thrombin generation inhibition to detect both protein C and protein S deficiencies in plasma. Thromb Haemost 1994; 71: 331-8
72. Hemker HC, Wielders S, Kessels H, Beguin S. Continuous registration of thrombin generation in plasma; its use for the determination of the thrombin potential. Thromb Haemost 1993; 70: 617-24
73. Mills AM, Wilkinson CL, Bromham DR, et al. Guidelines for prescribing combined oral contraceptives. Br Med J 1996; 312: 121-2
74. The European Agency for the Evaluation of Medicinal Products. Position Statement of the CPMP on oral contraceptives containing desogestrel or gestodene. London, 22 January 1997
75. Child TJ, Rees M, MacKenzie IZ. Pregnancy terminations after oral contraception scare. Lancet 1996; 347: 1260-1
76. Editorial. Public scares and public responsibility. Lancet 1996; 347: 1707